You are here : HOME / NETWORK / Loïc Ysebaert

Loïc Ysebaert

Prof. Loïc Ysebaert is Senior Haematologist and professor of Hematology since 2016 (University of Toulouse-3), working in the Comprehensive Cancer Centre of Toulouse, IUC Toulouse – Oncopôle, where he leads clinical and translational studies in the field of indolent and aggresive B-cell lymphomas. He is associate Researcher at the Inserm UMR1037-team 9, noLYMITS (novel lymphoma immune-therapeutic strategies).

He is member of the scientific boards of the LYmphoma Study Association (LYSA) and the French CLL study group (FiLO-LLC), and as such is the local coordinator for the trials led by these national collaborative groups. As an Associate Researcher at the Cancer Research Center of Toulouse), he is involved in translational research in the field of indolent B-cell lymphomas, especially how impact of tumor microenvironment on resistance towards immunotherapies (thanks to 3D modelling and single-cell transcriptomic analyses). Together with Julie GUILLERMET-GUIBERT, he participates to the PIPGEN network as a co-coordinator of the PhD project 12 “Treg evolution in B cell lymphoma patients under idelalisib”.

Publications

  • Molecular diagnosis of T-cell lymphoma: a correlative study of PCR-based T-cell clonality assessment and targeted NGS.
    Syrykh C, Gorez P, Péricart S, Grand D, Escudié F, Cabarrou B, Obéric L, Ysebaert L, Lamant L, Laurent C, Evrard SM, Brousset P. Blood Adv 2021;5(22):4590-4593.
  • Phased differentiation of γδ T and T CD8 tumor-infiltrating lymphocytes revealed by single-cell transcriptomics of human cancers
    Cerapio JP, Perrier M, Balança CC, Gravelle P, Pont F, Devaud C, Franchini DM, Féliu V, Tosolini M, Valle C, Lopez F, Quillet-Mary A, Ysebaert L, Martinez A, Delord JP, Ayyoub M, Laurent C, Fournie JJ. Oncoimmunology. 2021;10(1).
  • Lymphoma Heterogeneity Unraveled by Single-Cell Transcriptomics.
    Ysebaert L, Quillet-Mary A, Tosolini M, Pont F, Laurent C, Fournié JJ. Front Immunol. 2021;12: 597651.
  • Effects of novel Btk and Syk inhibitors on platelet functions alone and in combination in vitro and in vivo.
    Series J, Ribes A, Garcia C, Souleyreau P, Bauters A, Morschhauser F, Jürgensmeier JM, Sié P, Ysebaert L, Payrastre B. J Thromb Haemost. 2020;18(12):3336-3351.
  • Diagnosis and Treatment of Chronic Lymphocytic Leukemia: Recommendations of the French CLL Study Group (FILO).
    Quinquenel A, Aurran-Schleinitz T, Clavert A, Cymbalista F, Dartigeas C, Davi F, de Guibert S, Delmer A, Dilhuydy MS, Feugier P, Fornecker LM, Ghez D, Guieze R, Laribi K, Leblond V, Leprêtre S, Letestu R, Lévy V, Nguyen-Khac F, Michallet AS, Tomowiak C, Tournilhac O, Ysebaert L, Troussard X. Hemasphere. 2020;4(5):e473.
  • Lenalidomide/rituximab induces high molecular response in untreated follicular lymphoma: LYSA ancillary RELEVANCE study.
    Delfau-Larue MH, Boulland ML, Beldi-Ferchiou A, Feugier P, Maisonneuve H, Casasnovas RO, Lemonnier F, Pica GM, Houot R, Ysebaert L, Tilly H, Eisenmann JC, Le Gouill S, Ribrag V, Godmer P, Glaisner S, Cartron G, Xerri L, Salles GA, Fest T, Morschhauser F. Blood Adv. 2020;4(14):3217-3223.
  • Immunomodulatory Agents in Follicular Lymphoma.
    Ysebaert L, Morschhauser F. Hematol Oncol Clin North Am. 2020 Aug;34(4):715-726.
  • Sustained Progression-Free Survival Benefit of Rituximab Maintenance in Patients With Follicular Lymphoma: Long-Term Results of the PRIMA Study.
    Bachy E, Seymour JF, Feugier P, Offner F, López-Guillermo A, Belada D, Xerri L, Catalano JV, Brice P, Lemonnier F, Martin A, Casasnovas O, Pedersen LM, Dorvaux V, Simpson D, Leppa S, Gabarre J, da Silva MG, Glaisner S, Ysebaert L, Vekhoff A, Intragumtornchai T, Le Gouill S, Lister A, Estell JA, Milone G, Sonet A, Farhi J, Zeuner H, Tilly H, Salles G. J Clin Oncol. 2019;37(31):2815-2824.
  • Multiparametric analysis of CD8+ T cell compartment phenotype in chronic lymphocytic leukemia reveals a signature associated with progression toward therapy.
    Gonnord P, Costa M, Abreu A, Peres M, Ysebaert L, Gadat S, Valitutti S. Oncoimmunology. 2019;8(4):e1570774.
  • Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma.
    Morschhauser F, Fowler NH, Feugier P, Bouabdallah R, Tilly H, Palomba ML, Fruchart C, Libby EN, Casasnovas RO, Flinn IW, Haioun C, Maisonneuve H, Ysebaert L, Bartlett NL, Bouabdallah K, Brice P, Ribrag V, Daguindau N, Le Gouill S, Pica GM, Martin Garcia-Sancho A, López-Guillermo A, Larouche JF, Ando K, Gomes da Silva M, André M, Zachée P, Sehn LH, Tobinai K, Cartron G, Liu D, Wang J, Xerri L, Salles GA; RELEVANCE Trial Investigators. N Engl J Med. 2018;379(10):934-947.